MELOXICAM; RIZATRIPTAN BENZOATE - Generic Drug Details

What are the generic drug sources for meloxicam; rizatriptan benzoate and what is the scope of freedom to operate?

Meloxicam; rizatriptan benzoate is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for MELOXICAM; RIZATRIPTAN BENZOATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	MELOXICAM; RIZATRIPTAN BENZOATE at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for MELOXICAM; RIZATRIPTAN BENZOATE

M01AC	Oxicams
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for MELOXICAM; RIZATRIPTAN BENZOATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes

MELOXICAM; RIZATRIPTAN BENZOATE Market Analysis and Financial Projection

The pharmaceutical markets for meloxicam (an NSAID for arthritis/pain) and rizatriptan benzoate (a migraine therapy) exhibit distinct growth drivers, challenges, and financial trajectories. Below is a comparative analysis based on current trends and forecasts:

---

Meloxicam Market Dynamics

Growth Drivers

• Rising Arthritis Prevalence: Over 32.5 million U.S. adults have osteoarthritis, driving demand for pain management solutions[2][5].
• Aging Population: By 2050, the global population aged 60+ will double, increasing reliance on NSAIDs like meloxicam[6].
• Generic Penetration: Affordable generics dominate the market, with companies like Zydus and Cipla expanding their portfolios[1][10].

Financial Outlook

• Market Size: Valued at $1.2 billion (2024) to $7.34 billion (2024 estimates vary by source), projected to reach $13.5 billion by 2037 at a 4.8–10.7% CAGR[1][5][6].
• Regional Leadership: North America holds ~40% market share, but Asia-Pacific is expected to grow fastest due to healthcare access improvements[1][5].

Challenges

• Side Effects: Long-term NSAID use risks gastrointestinal and cardiovascular issues.
• Competition: Alternative therapies (e.g., biologics) and stringent regulations may slow growth[1][6].

---

Rizatriptan Benzoate Market Dynamics

Growth Drivers

• Migraine Prevalence: Affects 12% of the global population, with women 3x more likely to suffer[8][11].
• Improved Formulations: Oral dissolvable tablets and nasal sprays enhance patient compliance[3][9].
• Generic Availability: Teva and Merck lead production, reducing costs and broadening access[8][11].

Financial Outlook

• Market Size: Estimated at $1.2 billion (2024), projected to hit $2.5 billion by 2032 at a 5.5–6.7% CAGR[3][9].
• Regional Trends: North America/Europe dominate, but Asia-Pacific shows rapid growth due to rising healthcare spending[8][9].

Challenges

• Side Effects: Dizziness and chest tightness limit long-term use[11][12].
• Competition: Non-pharmacological treatments (e.g., CGRP inhibitors) pose market threats[8].

---

Comparative Analysis

Factor	Meloxicam	Rizatriptan Benzoate
Primary Use	Osteoarthritis, rheumatoid arthritis	Acute migraine relief
Market Size (2030s)	$13.5B–$34.4B[5][10]	$1.8B–$2.5B[8][9]
CAGR	4.8–10.7%	5.5–6.7%
Key Growth Region	Asia-Pacific	Asia-Pacific
Top Competitors	Zydus, Cipla, Boehringer-Ingelheim[6][10]	Teva, Merck, Glenmark[8][11]
Innovation Focus	Extended-release formulations[6]	Rapid-dissolve tablets, nasal sprays[3][9]

---

Future Opportunities

• Meloxicam: Expansion into emerging markets and combination therapies for enhanced efficacy[5][10].
• Rizatriptan Benzoate: Personalized migraine treatments and telemedicine-driven distribution[9][11].

Both markets face pressure from generics but benefit from aging populations and chronic disease prevalence. Meloxicam’s larger market size reflects broader applications, while rizatriptan benzoate’s niche focus on migraines aligns with targeted therapeutic advances.

References

1. https://github.com/amoakuolaopa/Market-Research-Report-List-1/blob/main/meloxicam-market.md
2. https://www.verifiedmarketreports.com/product/meloxicam-market/
3. https://www.marketresearchintellect.com/product/rizatriptan-benzoate-market-size-and-forecast/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC2014236/
5. https://www.researchnester.com/reports/meloxicam-market/5360
6. https://www.verifiedmarketreports.com/product/meloxicam-drug-market/
7. https://www.sec.gov/Archives/edgar/data/1579428/000095017024049222/2023_ars_for_2024_april_.pdf
8. https://www.verifiedmarketreports.com/product/rizatriptan-benzoate-market/
9. https://www.openpr.com/news/3918355/global-rizatriptan-benzoate-market-emerging-trends-and-growth
10. https://sites.google.com/view/mrp-13/mrp-13/meloxicam-drug-market-by-applications-2025
11. https://www.alliedmarketresearch.com/rizatriptan-benzoate-market-A15013
12. https://www.360iresearch.com/library/intelligence/meloxicam-drugs